Psychological interventions showed no clear difference in all‐cause mortality Medical records or reported by family members compared with usual care (low certainty).

1 finding from 1 review

Psychological interventions for diabetes‐related distress in adults with type 2 diabetes mellitus 2017 · Cochrane Headline outcomes only
RR 1.01 [0.17, 6.03]
3 studies · 1376 participants
Low

Intervention not reported

All‐cause mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2312 participants
Low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2281 participants
Very low

Intervention not reported

(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2279 participants
Very low

Intervention not reported

Health‐related quality of life SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1791 participants
Very low

Intervention not reported

Socioeconomic effects · people at risk for development of T2DM

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of T2DM Definition: WHO criteria · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2 participants
Very low